Based on these findings, PD-L1-positive patients are more likely to benefit from PD-1 immunotherapy, and the FDA has granted the accelerated approval of pembrolizumab for advanced gastric cancer treatment (7). The gene discussed is CD274; the disease is gastric cancer.